Cancer-Associated thrombosis

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 78-82

  Karimi, Mehran ^a   Cohan, Nader ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Low molecular weight heparin; Thrombosis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; CANCER PROCOAGULANT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR; WARFARIN;

ARTICLE; BLOOD CLOTTING; CANCER PATIENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG SAFETY; FOOD; FOOD DRUG INTERACTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; LUNG EMBOLISM; MONOTHERAPY; MORBIDITY; NEOPLASM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 78249263843     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010078     Document Type: Article

References (63)

1. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: 17-21.
2. White RH, Chew HK, Zhou H, et al. Incidence of venous throm-boembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165: 1782-1787.
3. Prandoni P, Piccioli A, Girolami A. Cancer and venous throm-boembolism: an overview. Haematologica 1999; 84: 437-445.
4. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4: 465-473.
5. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349: 109-111.
6. Sato T, Tsujino I, Ikeda D, Ieko M, Nishimura M. Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma. Thorax 2006; 61: 1009-1010.
7. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients re-ceiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-634.
8. Rickles FR, Falanga A. Molecular basis for the relationship be-tween thrombosis and cancer. Thromb Res 2001; 102: 215-224.
9. Deitcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 2003; 16: 21-31.
10. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555-568.
11. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park) 2003; 17: 126-135.
12. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
13. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. In-creased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731-2737.
14. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 2009; 27 (Suppl 1): 63-74.
15. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
16. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-294.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
18. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemo-therapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.
19. Donati MB. Cancer and thrombosis. Haemostasis 1994; 24: 128-131.
20. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997; 78: 141-144.
21. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recur-rent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-291.
22. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmo-nary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
23. Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 259-262.
24. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contracep-tives and cardiovascular disease. Ann Intern Med 1998; 128: 467-477.
25. Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res 2009; 123 (Suppl 4): 18-21.
26. Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol Haemost Thromb 2008; 36: 131-6.
27. Packard RR, Libby P. Inflammation in atherosclerosis: from vascu-lar biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
28. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
29. Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 2007; 120 (Suppl 2): 137-140.
30. López JA, Chen J. Pathophysiology of venous thrombosis. Thromb Res 2009; 123 (Suppl 4): S30-s34.
31. Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 2001; 73: 137-144.
32. Zwicker JI. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008; 34: 195-198.
33. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6: 1517-1524.
34. Lee AY. Cancer and thromboembolic disease: pathogenic mecha-nisms. Cancer Treat Rev 2002; 28: 137-140.
35. Rickles FR, Hair GA, Zeff RA, Lee E, Bona RD. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost 1995; 74: 391-395.
36. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-972.
37. Caine GJ, Lip GY, Zanetto U, Maheshwari M, Stonelake PS, Blann AD. A comparison of plasma versus histologic indices of angio-genic markers in breast cancer. Appl Immunohistochem Mol Mor-phol 2007; 15: 382-388.
38. Caine GJ, Stonelake PS, Lip GY, Blann AD. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Lett 2007; 248: 131-136.
39. Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, an-giopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004; 36: 273-277.
40. Lo SK, Cheung A, Zheng Q, Silverstein RL. Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol 1995; 154: 4768-4777.
41. Deitcher SR, Carman TL, Sheikh MA, Gomes M. Hypercoagulable syndromes: evaluation and management strategies for acute limb ischemia. Semin Vasc Surg 2001; 14: 74-85.
42. Dotsenko O, Kakkar AK. Thrombosis and cancer. Ann Oncol 2006; 17 (Suppl 10): 81-84.
43. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a popu-lation-based study. Arch Intern Med 2002; 162: 1245-8.
44. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60-68.
45. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast can-cer patients. J Clin Oncol 2007; 25: 70-76.
46. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24: 1112-1118.
47. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447.
48. Monreal M, Trujillo-Santos J. Screening for occult cancer in pa-tients with acute venous thromboembolism. Curr Opin Pulm Med 2007; 13: 368-371.
49. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemother-apy-associated thrombosis. Blood 2008; 111: 4902-4907.
50. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous throm-boembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
51. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl 3): 401S-428S.
52. Lee AY. Treatment of venous thromboembolism in cancer patients. Thromb Res 2001; 102: V195-208.
53. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, popu-lation-based cohort study. Br J Cancer 2004; 91: 92-95.
54. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retro-spective analysis. J Clin Oncol 2000; 18: 3078-3083.
55. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight hepa-rin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
56. Lee A. VTE in patients with cancer--diagnosis, prevention, and treatment. Thromb Res 2008; 123 (Suppl 1): 50-54.
57. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl): 489S-510S.
58. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophy-laxis in patients undergoing colorectal surgery: results of the cana-dian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001; 233: 438-444.
59. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-329.
60. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-346.
61. Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE pro-phylaxis in hospitalized cancer patients. Oncologist 2007; 12: 1361-1370.
62. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous throm-boembolism: the Seventh ACCP Conference on Antithrom-botic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 338S-400S.
63. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-1271.